Lv3
290 积分 2023-01-02 加入
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
1年前
已完结
Tirzepatide Once Weekly for the Treatment of Obesity
1年前
已完结
Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes
1年前
已完结
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
1年前
已完结
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
1年前
已完结
Advances in pharmacotherapies for hyperuricemia
1年前
已完结
Emerging Urate-Lowering Drugs and Pharmacologic Treatment Strategies for Gout: A Narrative Review
1年前
已完结
Contemporary medical, device, and surgical therapies for obesity in adults
1年前
已完结
Gout therapeutics and drug delivery
1年前
已完结
皖公网安备34019202002308
